Bone Marrow Transplant is a condition where the Insured Person needs necessary medical treatment to replace malignant or defective bone marrow with normal bone marrow from healthy donors to stimulate the production of formed blood cells.
Bone Marrow Transplant. Hematologic Disorders (one month)
Bone Marrow Transplant as defined herein and specifically listed in the applicable chapter of the Florida Administrative Code or covered by Medicare as described in the most recently published Medicare Coverage Issues Manual issued by the Centers for Medicare and Medicaid Services. We will cover the expenses incurred for the donation of bone marrow by a donor to the same extent such expenses would be covered for you and will be subject to the same limitations and exclusions as would be applicable to you. Coverage for the reasonable expenses of searching for a donor will be limited to a search among immediate family members and donors identified through the National Bone Marrow Donor Program;
Bone Marrow Transplant. Pre-hospitalization Medical Expenses or Post-hospitalization Medical Expenses of the organ donor.
Bone Marrow Transplant in press.
Bone Marrow Transplant. The actual undergoing of a transplant of any of the below organ as a recipient or the inclusion on an official transplant waiting list for any of the below organ: - One of the following whole human organs: heart, lung, liver, kidney, pancreas or - Human bone marrow using haematopoietic stem cells preceded by total bone marrow ablation. The transplant must be medically necessary and based on objective confirmation of organ failure. Other than the above stem cell transplants are excluded. The total loss of function of two or more limbs due to injury or disease of the spinal cord or brain, where such functional loss is considered to be permanent by a neurologist. Loss of function of limbs classified as Diplegia, Tetraplegia and Quadriplegia are included. Total irreversible loss of sight in both eyes as a result of illness or accident. The blindness must be certified by an ophthalmologist’s report. The blindness must not be able to be corrected by medical procedure.
Bone Marrow Transplant. Healthy bone marrow stem cells and the blood cells they create are crucial for survival, but certain diseases can affect the bone marrow, interfering with its ability to function properly. A bone marrow transplant is a process to replace unhealthy bone marrow with healthy bone marrow stem cells. Bone marrow transplant can save the lives of patients with blood cancers and genetic diseases and is a potential cure for patients with severe refractory autoimmune diseases. However, the high risks, toxic side effects and complexity of the procedure currently prevent many patients from being able to benefit. Heidelberg Pharma is an oncology specialist and the first company to develop the toxin Amanitin into cancer therapies using its proprietary Antibody Targeted Amanitin Conjugate (ATAC) technology and to advance the biological mode of action of the toxin as a novel therapeutic principle. This proprietary technology platform is being applied to develop the Company’s proprietary therapeutic ATACs as well as in third-party collaborations to create a variety of ATAC candidates. The proprietary lead candidate HDP-101 is a BCMA ATAC for multiple myeloma. ATAC technology is the core activity of subsidiary Heidelberg Pharma Research GmbH. Heidelberg Pharma AG has entered into partnerships to further develop and commercialize its clinical assets MESUPRON® and REDECTANE®, while RENCAREX® is available for out-licensing and further development. The Company is listed on the Frankfurt Stock Exchange: ISIN DE000A11QW0 / WKN A11QW / Symbol WL6. More information is available at xxx.xxxxxxxxxx-xxxxxx.xxx. Magenta Therapeutics is a biotechnology company developing therapeutics to revolutionize bone marrow transplant for patients with autoimmune diseases, blood cancers and genetic diseases. By creating a platform focused on critical areas of transplant medicine, Magenta Therapeutics is pioneering an integrated approach to extend the curative power of bone marrow transplant to more patients. Founded by internationally recognized leaders in bone marrow transplant medicine, Magenta Therapeutics was launched in 2016 by Third Rock Ventures and Atlas Venture and is headquartered in Cambridge, Mass. For more information, please visit xxx.xxxxxxxxx.xxx. Heidelberg Pharma AG Xxxxxx Xxxxxx Tel.: +00 00 00 00 00-00 Email: investors[at]xxxxxxxx.xxx Business Development Xx. Xxxxxx Xxxxxxx CBO, Executive Vice President Tel.: +00 0000 0000-00 Email: x.xxxxxxx[at]xxxxxxxx.xxx IR/PR support MC Serv...
Bone Marrow Transplant. A medical and/or surgical procedure comprised of several steps or stages including: • the harvest of stem cells or progenitor cells, whether from the bone marrow or from the blood, from a third-party donor (allogeneic transplant) or from the patient (autologous transplant); • processing and/or storage of the stem cells or progenitor cells after harvesting; • the administration of High-Dose Chemotherapy and/or High-Dose Radiation Therapy, when this step is prescribed by the treating Physician; • the infusion of the harvested stem cells or progenitor cells; and • hospitalization, observation and management of reasonably anticipated complications such as graft versus host disease, infections, bleeding, organ or system toxicities and low blood counts. The above definition of autologous Bone Marrow Transplant specifically includes transplants wherein the transplant component is derived from circulating blood in lieu of, or in addition to, harvested directly from the bone marrow, a procedure commonly known as peripheral stem cell or progenitor cell transplant or rescue procedure. This definition further specifically includes all component parts of the procedure including, without limitation, the High-Dose Chemotherapy and/or High-Dose Radiation Therapy.
Bone Marrow Transplant. I) The actual undergoing of a transplant of:
i. One of the following human organs: heart, lung, liver, kidney, pancreas, that resulted from irreversible end-stage failure of the relevant organ, or
ii. Human bone marrow using haematopoietic stem cells. The undergoing of a transplant has to be confirmed by a specialist medical practitioner.
II) The following are excluded:
i. Other stem-cell transplants
ii. Where only islets of langerhans are transplanted
Bone Marrow Transplant. Covered Services include certain services and supplies not otherwise excluded in this Plan and rendered in association with a covered transplant, including pre-transplant procedures such as organ harvesting (Donor Costs), post-operative care (including antirejection drug treatment, if Prescription Drugs are covered under the Plan) and transplant related chemotherapy for cancer limited as follows. A transplant means procedure or series of procedures by which an organ or tissue is either: x Removed from the body of one person (called a donor) and implanted in the body of another person (called a recipient); or x Removed from and replaced in the saûǦ ÐǦdCŽY’C á-dŽonEorfl). ;ÐǍnnǦE Ǎ
